140 related articles for article (PubMed ID: 15290343)
1. The multifaceted role of transglutaminase in neurodegeneration: review article.
Karpuj M; Steinman L
Amino Acids; 2004 Jul; 26(4):373-9. PubMed ID: 15290343
[TBL] [Abstract][Full Text] [Related]
2. Critical role of transglutaminase and other stress proteins during neurodegenerative processes.
Caccamo D; Currò M; Condello S; Ferlazzo N; Ientile R
Amino Acids; 2010 Feb; 38(2):653-8. PubMed ID: 19960212
[TBL] [Abstract][Full Text] [Related]
3. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
Wilhelmus MM; van Dam AM; Drukarch B
Eur J Pharmacol; 2008 May; 585(2-3):464-72. PubMed ID: 18417122
[TBL] [Abstract][Full Text] [Related]
4. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.
Karpuj MV; Becher MW; Springer JE; Chabas D; Youssef S; Pedotti R; Mitchell D; Steinman L
Nat Med; 2002 Feb; 8(2):143-9. PubMed ID: 11821898
[TBL] [Abstract][Full Text] [Related]
5. Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
Martin A; Giuliano A; Collaro D; De Vivo G; Sedia C; Serretiello E; Gentile V
Amino Acids; 2013 Jan; 44(1):111-8. PubMed ID: 21938398
[TBL] [Abstract][Full Text] [Related]
6. [Transglutaminase and neurodegenerative diseases].
Liu Z; Zeng J; Zeng S; Tang B; Wang J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Aug; 32(4):562-6. PubMed ID: 26252108
[TBL] [Abstract][Full Text] [Related]
7. New target against inflammatory diseases: transglutaminase 2.
Kim SY
Arch Immunol Ther Exp (Warsz); 2004; 52(5):332-7. PubMed ID: 15507874
[TBL] [Abstract][Full Text] [Related]
8. Neurodegeneration and peroxidases.
Everse J; Coates PW
Neurobiol Aging; 2009 Jul; 30(7):1011-25. PubMed ID: 18053617
[TBL] [Abstract][Full Text] [Related]
9. Reduced transglutaminase-catalyzed protein aggregation is observed in the presence of creatine using sedimentation velocity.
Burguera EF; Love BJ
Anal Biochem; 2006 Mar; 350(1):113-9. PubMed ID: 16445883
[TBL] [Abstract][Full Text] [Related]
10. Transglutaminases - possible drug targets in human diseases.
Gentile V; Cooper AJ
Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):99-104. PubMed ID: 15078184
[TBL] [Abstract][Full Text] [Related]
11. GTP is required to stabilize and display transamidation activity of transglutaminase 2.
Jeon JH; Cho SY; Kim CW; Shin DM; Kweon JC; Choi KH; Park SC; Kim IG
Biochem Biophys Res Commun; 2002 Jun; 294(4):818-22. PubMed ID: 12061780
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase is linked to neurodegenerative diseases.
Muma NA
J Neuropathol Exp Neurol; 2007 Apr; 66(4):258-63. PubMed ID: 17413316
[TBL] [Abstract][Full Text] [Related]
13. Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease and neurodegenerative diseases: from basic biochemistry to clinic.
Martin A; Romito G; Pepe I; De Vivo G; Merola MR; Limatola A; Gentile V
Curr Med Chem; 2006; 13(16):1895-902. PubMed ID: 16842200
[TBL] [Abstract][Full Text] [Related]
14. Transglutaminase-catalyzed crosslinking in neurological disease: from experimental evidence to therapeutic inhibition.
Hoffner G; André W; Vanhoutteghem A; Souès S; Djian P
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):217-31. PubMed ID: 19811443
[TBL] [Abstract][Full Text] [Related]
15. Lysine-rich histone (H1) is a lysyl substrate of tissue transglutaminase: possible involvement of transglutaminase in the formation of nuclear aggregates in (CAG)(n)/Q(n) expansion diseases.
Cooper AJ; Wang J; Pasternack R; Fuchsbauer HL; Sheu RK; Blass JP
Dev Neurosci; 2000; 22(5-6):404-17. PubMed ID: 11111157
[TBL] [Abstract][Full Text] [Related]
16. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor.
Case A; Stein RL
Biochemistry; 2007 Jan; 46(4):1106-15. PubMed ID: 17240993
[TBL] [Abstract][Full Text] [Related]
17. [Aggregation and toxicity of the proteins with polyQ repeats].
Leźnicki P
Postepy Biochem; 2005; 51(2):215-22. PubMed ID: 16209359
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability.
Cooper AJ; Sheu KF; Burke JR; Strittmatter WJ; Gentile V; Peluso G; Blass JP
J Neurochem; 1999 Mar; 72(3):889-99. PubMed ID: 10037459
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
Iannaccone M; Serretiello E; De Vivo G; Martin A; Stefanile A; Titta F; Gentile V
Recent Pat CNS Drug Discov; 2013 Aug; 8(2):161-8. PubMed ID: 23688272
[TBL] [Abstract][Full Text] [Related]
20. Transglutaminase as the agent of neurodegenerative diseases due to polyglutamine expansion.
Kahlem P; Green H; Djian P
Pathol Biol (Paris); 1998 Nov; 46(9):681-2. PubMed ID: 9885815
[No Abstract] [Full Text] [Related]
[Next] [New Search]
